William D. Waddill's most recent trade in Protagonist Therapeutics Inc was a trade of 20,000 Common Stock done at an average price of $8.3 . Disclosure was reported to the exchange on Feb. 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.31 per share. | 06 Feb 2026 | 20,000 | 27,825 (0%) | 0% | 8.3 | 166,200 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 83.68 per share. | 06 Feb 2026 | 20,000 | 7,825 (0%) | 0% | 83.7 | 1,673,600 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,762 | 3,762 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 2,695 | 7,825 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharma Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 68.01 per share. | 19 Dec 2025 | 5,451 | 57,063 (0%) | 0% | 68.0 | 370,723 | Common Stock |
| Arrowhead Pharma Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 66.66 per share. | 19 Dec 2025 | 2,416 | 62,514 (0%) | 0% | 66.7 | 161,051 | Common Stock |
| Arrowhead Pharma Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 68.53 per share. | 19 Dec 2025 | 500 | 56,563 (0%) | 0% | 68.5 | 34,265 | Common Stock |
| Arrowhead Pharma Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2025 | 7,819 | 64,930 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Oct 2025 | 12,000 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.98 per share. | 10 Oct 2025 | 12,000 | 17,130 (0%) | 0% | 7.0 | 83,760 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 87.81 per share. | 10 Oct 2025 | 8,000 | 5,130 (0%) | 0% | 87.8 | 702,480 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 69.25 per share. | 10 Oct 2025 | 4,000 | 13,130 (0%) | 0% | 69.3 | 277,000 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 64.25 per share. | 22 Sep 2025 | 4,000 | 5,130 (0%) | 0% | 64.3 | 257,000 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 59.25 per share. | 27 Aug 2025 | 4,000 | 9,130 (0%) | 0% | 59.3 | 237,000 | Common Stock |
| Annexon Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 54.25 per share. | 17 Mar 2025 | 4,000 | 13,130 (0%) | 0% | 54.3 | 217,000 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,584 | 6,584 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 5,130 | 17,130 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharma Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 22.99 per share. | 18 Dec 2024 | 16,733 | 57,111 (0%) | 0% | 23.0 | 384,692 | Common Stock |
| Arrowhead Pharma Inc | D. William Waddill | Director | Sale of securities on an exchange or to another person at price $ 21.90 per share. | 16 Dec 2024 | 3,748 | 44,125 (0%) | 0% | 21.9 | 82,081 | Common Stock |
| Arrowhead Pharma Inc | Waddill D. William | Director | Sale of securities on an exchange or to another person at price $ 22.04 per share. | 16 Dec 2024 | 3,747 | 40,378 (0%) | 0% | 22.0 | 82,584 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.88 per share. | 10 Sep 2024 | 8,000 | 20,000 (0%) | 0% | 12.9 | 103,040 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 8,000 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 10 Sep 2024 | 8,000 | 12,000 (0%) | 0% | 45 | 360,000 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2024 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 24 Jul 2024 | 8,000 | 12,000 (0%) | 0% | 40 | 320,000 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.88 per share. | 24 Jul 2024 | 8,000 | 20,000 (0%) | 0% | 12.9 | 103,040 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 8,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 07 Jun 2024 | 8,000 | 12,000 (0%) | 0% | 35 | 280,000 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.88 per share. | 07 Jun 2024 | 8,000 | 20,000 (0%) | 0% | 12.9 | 103,040 | Common Stock |
| Annexon Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Turnstone Biologics Corp | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 12,770 | 12,770 | - | - | Stock Option (Right to Buy) | |
| Turnstone Biologics Corp | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 25,540 | 25,540 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 12,975 | 0 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 31.34 per share. | 01 Mar 2024 | 12,975 | 12,000 (0%) | 0% | 31.3 | 406,637 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.09 per share. | 01 Mar 2024 | 12,975 | 24,975 (0%) | 0% | 6.1 | 79,018 | Common Stock |
| Arrowhead Pharma Inc | Waddill William D. | Director | Sale of securities on an exchange or to another person at price $ 37.81 per share. | 11 Jan 2024 | 2,634 | 49,170 (0%) | 0% | 37.8 | 99,592 | Common Stock |
| Arrowhead Pharma Inc | D. Waddill William | Director | Sale of securities on an exchange or to another person at price $ 38.59 per share. | 11 Jan 2024 | 1,300 | 47,870 (0%) | 0% | 38.6 | 50,167 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 25,700 | 25,700 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharma Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 25.41 per share. | 15 Dec 2023 | 14,987 | 51,804 (0%) | 0% | 25.4 | 380,820 | Common Stock |
| Annexon Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharma Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 7,867 | 36,817 (0%) | 0% | 0 | Common Stock | |
| Arrowhead Pharma Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2023 | 4,593 | 4,593 | - | - | Common Stock | |
| Arrowhead Pharma Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 09 Jan 2023 | 3,200 | 28,950 (0%) | 0% | 30 | 96,000 | Common Stock |
| Annexon Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.59 per share. | 03 May 2022 | 12,000 | 12,000 (0%) | 0% | 8.6 | 103,080 | Common Stock |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 12,000 | 0 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharma Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 65.01 per share. | 03 Jan 2022 | 2,128 | 26,022 (0%) | 0% | 65.0 | 138,341 | Common Stock |
| Arrowhead Pharma Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 64.23 per share. | 03 Jan 2022 | 2,100 | 28,150 (0%) | 0% | 64.2 | 134,883 | Common Stock |
| Arrowhead Pharma Inc | William D. Waddill | Director | Sale of securities on an exchange or to another person at price $ 66.25 per share. | 03 Jan 2022 | 272 | 25,750 (0%) | 0% | 66.3 | 18,020 | Common Stock |
| Annexon Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | William D. Waddill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) |